H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

NCT05167643 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced HR+ HER2 Negative Breast Carcinoma

Interventions

DRUG: Enituzumab injection+Abesili tablets+Anastrozole tablets

Sponsor

Tianjin Medical University Cancer Institute and Hospital